Evaluation of never-smoking status and male gender as clinical predictive factors for survival with erlotinib treatment of non-small cell lung cancer.

e18134 Background: In non-small cell lung cancer (NSCLC), EGFR-mutation status predicts response to treatment with erlotinib. However, often EGFR-mutation analysis is not available. Therefore, clin...